Multiple sclerosis and related disorders · 2026
Serum angiogenesis-hypoxia biomarkers in relapsing-remitting multiple sclerosis.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yong Heather Y F, Batty Nicholas J, Phillips Serena, Ghuman Mankarman, Zhang Yunyan, Camara-Lemarroy Carlos
Аннотация
BACKGROUND: Studies have demonstrated that the hypoxia-angiogenic axis is dysregulated in progressive multiple sclerosis (MS), with an upregulation of hypoxic biomarkers with a paradoxical reduction of angiogenic biomarkers. In this study, we postulated that the hypoxia-angiogenic axis would be relatively preserved in relapsing-remitting MS (RRMS; a predominantly neuroinflammatory driven process) as opposed to its progressive counterpart (predominantly neurodegenerative driven).
METHODS: Serum samples were collected from RRMS participants screened for a randomized pilot trial of domperidone as adjunct therapy, prior to initiation of the study drug (n=122), and matched to healthy controls (n=78). Angiogenic factors were measured with a commercially available bead-based multiplex assay and hypoxia biomarkers were measured with a custom bead-based multiplex assay. Publicly available transcriptomic databases of the RRMS brain were utilized to investigation the expression of selected hypoxia/angiogenic markers in the central nervous system (CNS).
RESULTS: Circulating hypoxic markers (hypoxia inducible factor-1-a, heme oxygenase-1, and heat shock protein-90) were increased in the serum and CNS of people with RRMS. Conversely, brain derived neurotrophic factor was reduced. Lysyl oxidase levels correlated with lesion texture (r=(-)0.28) and brain volume (r=(-)0.24). Angiogenic markers were not significantly dysregulated.
CONCLUSION: Hypoxic factors are upregulated in RRMS serum and CNS, while angiogenesis factors are unchanged. This may suggest preservation of the hypoxia-angiogenic axis in RRMS as compared to the dysregulation seen in progressive MS.
METHODS: Serum samples were collected from RRMS participants screened for a randomized pilot trial of domperidone as adjunct therapy, prior to initiation of the study drug (n=122), and matched to healthy controls (n=78). Angiogenic factors were measured with a commercially available bead-based multiplex assay and hypoxia biomarkers were measured with a custom bead-based multiplex assay. Publicly available transcriptomic databases of the RRMS brain were utilized to investigation the expression of selected hypoxia/angiogenic markers in the central nervous system (CNS).
RESULTS: Circulating hypoxic markers (hypoxia inducible factor-1-a, heme oxygenase-1, and heat shock protein-90) were increased in the serum and CNS of people with RRMS. Conversely, brain derived neurotrophic factor was reduced. Lysyl oxidase levels correlated with lesion texture (r=(-)0.28) and brain volume (r=(-)0.24). Angiogenic markers were not significantly dysregulated.
CONCLUSION: Hypoxic factors are upregulated in RRMS serum and CNS, while angiogenesis factors are unchanged. This may suggest preservation of the hypoxia-angiogenic axis in RRMS as compared to the dysregulation seen in progressive MS.